Mechanisms of immunotherapy: IgG revisited

Current Opinion in Allergy and Clinical Immunology

Volumn 4, Issue 4, 2004, Pages 313-318

  Wachholz, Petra A ^a,c   Durham, Stephen R ^b  

^a CTL   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^c CTL   (United Kingdom)

Author keywords

Antibody affinity; Antibody specificity; IgE facilitated allergen presentation; IgG blocking antibodies; Specific immunotherapy

Indexed keywords

ALLERGEN; CYTOKINE; EPITOPE; HISTAMINE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G4; POLLEN ANTIGEN; RECOMBINANT ALLERGEN; UNCLASSIFIED DRUG;

ALLERGY; ANTIBODY RESPONSE; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; B LYMPHOCYTE; HISTAMINE RELEASE; HUMAN; IMMUNIZATION; IMMUNOTHERAPY; NONHUMAN; POLLEN ALLERGY; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

HUMANS; HYPERSENSITIVITY; IMMUNOGLOBULIN G; IMMUNOTHERAPY;

EID: 3442888237     PISSN: 15284050     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.all.0000136753.35948.c0     Document Type: Review

References (50)

1. Durham SR, Till SJ. Immunological changes associated with allergen immunotherapy. J Allergy Clin Immunol 1998; 102:157-164.
2. Ebner C. Immunological mechanisms operative in allergen-specific immunotherapy. Int Arch Allergy Immunol 1999; 119:1-5.
3. Ewan PW, New insight into immunological mechanisms of venom immunotherapy [Review]. Curr Opin Allergy Clin Immunol 2001; 1:367-374.
4. Muller U, Helbling A, Bischof M. Predictive value of venom-specific IgE, IgG and 19G subclass antibodies in patients on immunotherapy with honey bee venom. Allergy 1989; 44:412-418.
5. Ewan PW, Deighton J, Wilson AB, Lachmann PJ. Venom-specific IgG antibodies in bee and wasp allergy: lack of correlation with protection from stings. Clin Exp Allergy 1993; 23:647-660.
6. Ball T, Sperr WR, Valent P, et al. Induction of antibody responses to new B cell epitopes indicates vaccination character of allergen immunotherapy. Eur J Immunol 1999; 29:2026-2036.
7. Michils A, Ledent C, Mairesse M, et al. Wasp venom immunotherapy changes IgG antibody specificty. Clin Exp Allergy 1997; 27:1036-1042.
8. Michils A, Mairesse M, Ledent C, et al. Modified antigenic reacitivty to antiphospholipase A2 IgG antibodies in patients allergic to bee venom: conversion with immunotherapy and relation to subclass expression. J Allergy Clin Immunol 1998; 102:118-126.
9. Ball T, Fuchs T, Sperr WR, et al. B cell epitopes of the major timothy grass pollen allergen, Phl p 1, revealed by gene fragmentation as candidates for immunotherapy. Faseb J 1999; 13:1277-1290.
10. van Neerven RJ, Wikborg T, Lund G, et al. Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4+ T cells by inhibiting serum-19E-facilitated allergen presentation. J Immunol 1999; 163:2944-2952.
11. Wachholz PA, Kristensen Soni N, Till SJ, Durham SR. Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy. J Allergy Clin Immunol 2003; 112:915-922.
12. van Neerven RJJ, Arvidsson M, Ipsen H, et al. A double-blind, placebo-controlled birch allergy vaccination study: inhibition of CD23-mediated serum-immunoglobulin E-facilitated allergen presentation. Clin Exp Allergy 2004; 34:420-428.
13. Ravetch JV, Bolland S. IgG Fc receptors. Annu Rev Immunol 2001; 19:275-290.
14. Coggeshall KM. Inhibitory signaling by B cell Fc gamma RIIb [Review]. Curr Opin Immunol 1998; 10:306-312.
15. Nouri-Aria KT, Wachholz PA, Francis JN, et al. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol 2004; 172:3252-3259.
16. Golden DBK, Lawrence ID, Kagey-Sobotka A, et al. Clinical correlation of the venom-specific IgG antibody level during maintenance venom immunotherapy. J Allergy Clin Immunol 1992; 90:386-393.
17. Aalberse RC, van der Gaag R, van der Leeuwen J. Serological aspects of IgG4 antibodies. I. Prolonged immunization results in an IgG4-restricted response. J Immunol 1983; 130:722-726.
18. Platts-Mills T, Vaughan J, Squillace S, et al. Sensitisation, asthma, and a modified Th2 response in children exposed to cat allergen: a population-based cross-sectional study. Lancet 2001; 357:752-756.
19. Platts-Mills T, Vaughan JW, Blumenthal K, et al. Serum IgG and IgG4 antibodies to Fel d 1 among children exposed to 20 microg Fel d 1 at home: relevance of a nonallergic modified Th2 response. Int Arch Allergy Immunol 2001; 124:126-129.
20. Platts-Mills T, Vaughan JW, Blumenthal K, et al. Decreased prevalence of asthma among children with high exposure to cat allergen: relevance of the modified Th2 response [Review]. Mediat Inflamm 2001; 10:288-291.
21. Djurup R, Malling HJ. High IgG4 antibody level is associated with failure of immunotherapy with inhalant allergens, Clin Allergy 1987; 17:459-468.
22. Boluda L, de la Cuadra B, Berrens L. Binding affinities of allergens from pollen, mites, and house dust for specific IgG subclass antibodies. Allergy 1996; 51:706-711.
23. Visco V, Dolecek C, Denepoux S, et al. Human IgG monoclonal antibodies that modulate binding of specific IgE to birch pollen Bet v 1. J Immunol 1996; 157:956-962.
24. Denepoux S, Eibensteiner P, Steinberger P, et al. Molecular characterization of human IgG monoclonal antibodies specific for the major birch pollen allergen Bet v 1. Anti-allergen IgG can enhance the anaphylactic reaction. FEBS Lett 2000; 465:39-46.
25. Duchateau J, Michils A, Michel O, Baras L. Mite allergy is associated with a specific profile of IgG epitopes recognized on antigen p 1 of Dermatophagoides pteronyssinus. Clin Exp Allergy 1997; 27:296-305.
26. Michils A, Vervier I, Choufani G, et al. Relationship between allergic status and specificity of IgG antibody to inhaled allergens: the grass pollen model, Clin Exp Allergy 1999; 29:832-839.
27. Cooke RA, Barnard JH, Hebald S, Stull A. Serological evidence of immunity with coexisting sensitisation in a type of human allergy (hay fever). J Exp Med 1935; 62:733-751.
28. Loveless MH. Immunological studies of pollinosis. I. The presence of two antibodies related to the same pollen antigen in serum of treated hay fever patients. J Immunol 1940; 38:25-50.
29. Loveless MH. Immunological studies of pollinosis. IV. The relationship between thermo stable antibody in the circulation and clinical immunity. J Immunol 1943; 47:165-180.
30. Lichtenstein LM, Holtzman NA, Burnett LS. A quantitative study of the chromatographic distribution and immunoglobulin characteristics of human blocking antibody. J Immunol 1968; 101:317-324.
31. Hussain R, Poindexter RW, Ottesen EA. Control of allergic reactivity in human filariasis. Predominant localization of blocking antibody to the IgG4 subclass. J Immunol 1992; 148:2731-2737.
32. Batard T, Basuyaux B, Lambin P, et al. Isotypic analysis of grass pollen-specific immunoglobulins in human plasma. 1. Specialization of certain classes and subclasses in the immune response. Int Arch Allergy Immunol 1993; 100:68-78.
33. Zhu D, Kepley CL, Zhang M, et al. A novel human immunoglobulin Fc gamma Fc epsilon bifunctional fusion protein inhibits Fc epsilon RI-mediated degranulation. Nat Med 2002; 8:518-521.
34. van der Heijden FL, van Neerven RJ, van Katwijk M, et al. Serum-IgE facilitated allergen presentation in atopic disease. J Immunol 1993; 150:3643-3650.
35. Stingl G. IgE-mediated, FcεRI-dependent allergen presentation: a pathogenetic factor in atopic dermatitis? J Am Acad Dermatol 2001; 45(Suppl 1):S17-S20.
36. Novak N, Kraft S, Bieber T. Unraveling the mission of FcεRI on antigen-presenting cells. J Allergy Clin Immunol 2003; 111:38-44. A comprehensive review article covering the structural and molecular aspects of FcεRI expression on antigen-presenting cells, with a focus on Langerhans' cells.
37. Mudde GC, Bheekha R, Bruijnzeel-Koomen CA. IgE-mediated antigen presentation. Allergy 1995; 50:193-199.
38. Maurer D, Fiebiger E, Reininger B, et al. Fcε receptor on dendritic cells delivers IgE-bound multivalent antigens into a cathepsin S-dependent pathway of MHC class II presentation. J Immunol 1998; 161:2731-2739.
39. Jeannin P, Lecoanet S, Delneste Y, et al. IgE versus IgG4 production can be differentially regulated by IL-10. J Immunol 1998; 160:3555-3561.
40. Lambin P, Bouzoumou A, Murrieta M, et al. Purification of human IgG4 subclass with allergen-specific blocking activity. J Immunol Methods 1993; 165:99-111.
41. Jensen-Jarolim E, Vogel M, de Weck AL, Stadler BM. Anti-IgE autoantibodies mistaken for specific IgG. J Allergy Clin Immunol 1992; 89:31-43.
42. Smith AM, Chapman MD. Reduction in IgE binding to allergen variants generated by site-directed mutagenesis: contribution of disulfide bonds to the antigenic structure of the major house dust mite allergen Der p 2. Mol Immunol 1996; 33:399-405.
43. Focke M, Mahler V, Ball T, et al. Nonanaphylactic synthetic peptides derived from B cell epitopes of the major grass pollen allergen, Phl p 1, for allergy vaccination. Faseb J 2001; 15:2042-2044.
44. Vrtala S, Hirtenlehner K, Susani M, et al. Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen Set v 1. Faseb J 2001; 15:2045-2047.
45. Müller UR, Recombinant Hymenoptera venom allergens, Allergy 2002; 57:570-576.
46. Müller U, Fricker M, Wymann D, et al. Increased specificity of diagnostic tests with recombinant major bee venom allergen phospholipase A2. Clin Exp Allergy 1997; 27:915-920.
47. Valenta R, Lidholm J, Niederberger V, et al. The recombinant allergen-based concept of component resolved diagnostics and immunotherapy. Clin Exp Allergy 1999; 29:896-904.
48. King TP, Jim SY, Monsalve RI, et al. Recombinant allergens with reduced allergenicity but retaining immunogenicity of the natural allergens: hybrids of yellow jacket and paper wasp venom allergen antigen 5s1. J Immunol 2001; 166:6057-6065.
49. Linhart B, Jahn-Schmid B, Verdino P, et al. Combination vaccines for the treatment of grass pollen allergy consisting of genetically engineered hybrid molecules with increased immunogenicity. Faseb J 2002; 16:1301-1303.
50. Flicker S, Steinberger P, Norderhaug L, et al. Conversion of grass pollen allergen-specific human IgE into a protective IgG(1) antibody. Eur J Immunol 2002; 32:2156-2162.